How many clinical trials are studying Ocrelizumab?

7 recruiting trials in our tracked data involve Ocrelizumab.

What conditions is Ocrelizumab being studied for?

In our tracked recruiting trials, Ocrelizumab is being studied in trials for Multiple Sclerosis, Progressive Multiple Sclerosis, Relapsing Multiple Sclerosis.

Ocrelizumab: clinical trials recruiting now

Q: Is Ocrelizumab FDA-approved?

Yes. According to the FDA drug label available through openFDA, Ocrelizumab is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Ocrelizumab appears in the FDA drug-label database. Marketed as OCREVUS.
Drug class: CD20-directed Cytolytic Antibody (FDA established pharmacologic class)
Mechanism of action: CD20-directed Antibody Interactions (as stated on the FDA label)

FDA-approved use

OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more. OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 ) Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more ( 1 )

FDA label via openFDA

Phase breakdown

Phase 2 1 Phase 3 3 Phase 4 2 Not applicable 1

Conditions being studied

Condition	Trials
Multiple Sclerosis · Ocrelizumab for Multiple Sclerosis	7
Progressive Multiple Sclerosis	1
Relapsing Multiple Sclerosis	1
Relapsing-remitting Multiple Sclerosis (RRMS)	1

Recruiting trials involving Ocrelizumab

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT07321093 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 108 locations
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
NCT06780150 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 92 locations
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · 129 locations
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891 · Phase: Phase 4 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 13 locations
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
NCT07389590 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location

Common questions

Is Ocrelizumab FDA-approved?

Yes, marketed as OCREVUS.

How many recruiting trials involve Ocrelizumab?

7 recruiting trials across 4 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.